Company intelligence / Profile preview
Beijing Tuojie Biomedical Technology Co., Ltd.
Beijing, Beijing, Chinapharmaceutical-technology.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
The company has a total of 6 products in development, with their lead candidate BJTJ-0003 in Phase II clinical trials for thrombosis. They also have 3 products in discovery stage and 2 in Phase I. BJTJ-0003 has a 57% phase transition success rate for progressing into Phase III.
- Therapeutic areas
- Metabolic DisordersCardiovascularRheumatologyNeurology
- Modalities
- Small molecule drugRecombinant polypeptideFusion proteinBiological productsChemical drugsSynthetic peptideMonoclonal antibodyPeptide
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Beijing Tuojie Biomedical Technology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing Tuojie Biomedical Technology Co., Ltd..